Sanofi SA (EPA:SAN) received a €92.00 ($108.24) price target from equities research analysts at Morgan Stanley in a research report issued on Friday. The brokerage currently has a “buy” rating on the stock.

Several other research firms have also recently weighed in on SAN. J P Morgan Chase & Co set a €90.00 ($105.88) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Tuesday, August 1st. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Tuesday, August 1st. S&P Global set a €90.00 ($105.88) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Berenberg Bank set a €97.00 ($114.12) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Finally, Sanford C. Bernstein set a €90.00 ($105.88) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. Sanofi SA presently has an average rating of “Hold” and an average target price of €87.88 ($103.38).

Sanofi SA (SAN) traded up 0.58% on Friday, hitting €86.18. 835,796 shares of the stock were exchanged. The company has a 50-day moving average of €26.12 and a 200-day moving average of €26.01. The stock has a market cap of €108.22 billion and a price-to-earnings ratio of 12.02. Sanofi SA has a 12 month low of €24.55 and a 12 month high of €86.22.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Reiterates €92.00 Price Target for Sanofi SA (SAN)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/06/morgan-stanley-reiterates-92-00-price-target-for-sanofi-sa-san.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.